MS
ADMA icon

Maven Securities’s ADMA Biologics ADMA Stock Holding History

Maven Securities’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35,000
Closed -$513K – 456
2025
Q3 		$513K Buy
+35,000
New +$600K 0.01% 409
2024
Q2 		– Sell
-50,000
Closed -$330K – 900
2024
Q1 		$330K Buy
+50,000
New +$273K 0.02% 264
2023
Q2 		– Sell
-50,000
Closed -$166K – 844
2023
Q1 		$166K Buy
+50,000
New +$173K ﹤0.01% 889
2022
Q4 		– Sell
-15,000
Closed -$37K – 814
2022
Q3 		$37K Sell
15,000
-454,206
-97% -$1.09M ﹤0.01% 1077
2022
Q2 		$929K Sell
469,206
-3,022,318
-87% -$5.95M 0.03% 388
2022
Q1 		$6.39M Buy
3,491,524
+175,917
+5% +$274K 0.22% 67
2021
Q4 		$4.67M Buy
+3,315,607
New +$4.36M 0.13% 94
2021
Q2 		– Sell
-750,325
Closed -$1.32M – 1017
2021
Q1 		$1.32M Buy
+750,325
New +$1.72M 0.06% 316

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Maven Securities's ADMA Position: Q4 2025 in Review

Maven Securities sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 35,000 shares — an estimated $513K sold.

Maven Securities first reported a position in ADMA in Q1 2021 and held it in 8 quarters. The position peaked at $6.39M in Q1 2022. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Maven Securities reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Maven Securities sold 35,000 ADMA Biologics shares in Q4 2025, an estimated $513K.
  • Maven Securities first reported a position in ADMA Biologics in Q1 2021 and held it in 8 quarters.
  • Maven Securities's ADMA Biologics position peaked at $6.39M in Q1 2022.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Maven Securities's 13F filing for Q4 2025, filed 13 Feb 2026.